Cargando…
Metabolomics in High Grade Gliomas
Gliomas are central nervous system (CNS) cancers that are challenging to treat due to their high proliferation and mutation rates. High grade gliomas include grade 3 and grade 4 tumors, which characteristically have a poor prognosis despite advancements in diagnostic methods and therapeutic options....
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839194/ https://www.ncbi.nlm.nih.gov/pubmed/36643416 http://dx.doi.org/10.51520/2766-2586-17 |
_version_ | 1784869434620379136 |
---|---|
author | Yu, Nina Aboud, Orwa |
author_facet | Yu, Nina Aboud, Orwa |
author_sort | Yu, Nina |
collection | PubMed |
description | Gliomas are central nervous system (CNS) cancers that are challenging to treat due to their high proliferation and mutation rates. High grade gliomas include grade 3 and grade 4 tumors, which characteristically have a poor prognosis despite advancements in diagnostic methods and therapeutic options. Advances in metabolomics are resulting in more insight as to how cancer modifies the metabolism of the cell and surrounding tissue. Hence, this avenue of research may also emerge as a way to precisely target metabolites unique to gliomas. These biomarkers may provide opportunities for glioma diagnosis, prognosis and future therapeutic intervention. In this review, we harvest the literature that highlights notable biomolecules in high grade gliomas and promising therapeutic targets and interventions. |
format | Online Article Text |
id | pubmed-9839194 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
record_format | MEDLINE/PubMed |
spelling | pubmed-98391942023-01-13 Metabolomics in High Grade Gliomas Yu, Nina Aboud, Orwa RAS Oncol Ther Article Gliomas are central nervous system (CNS) cancers that are challenging to treat due to their high proliferation and mutation rates. High grade gliomas include grade 3 and grade 4 tumors, which characteristically have a poor prognosis despite advancements in diagnostic methods and therapeutic options. Advances in metabolomics are resulting in more insight as to how cancer modifies the metabolism of the cell and surrounding tissue. Hence, this avenue of research may also emerge as a way to precisely target metabolites unique to gliomas. These biomarkers may provide opportunities for glioma diagnosis, prognosis and future therapeutic intervention. In this review, we harvest the literature that highlights notable biomolecules in high grade gliomas and promising therapeutic targets and interventions. 2022 2022-09-30 /pmc/articles/PMC9839194/ /pubmed/36643416 http://dx.doi.org/10.51520/2766-2586-17 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Yu, Nina Aboud, Orwa Metabolomics in High Grade Gliomas |
title | Metabolomics in High Grade Gliomas |
title_full | Metabolomics in High Grade Gliomas |
title_fullStr | Metabolomics in High Grade Gliomas |
title_full_unstemmed | Metabolomics in High Grade Gliomas |
title_short | Metabolomics in High Grade Gliomas |
title_sort | metabolomics in high grade gliomas |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839194/ https://www.ncbi.nlm.nih.gov/pubmed/36643416 http://dx.doi.org/10.51520/2766-2586-17 |
work_keys_str_mv | AT yunina metabolomicsinhighgradegliomas AT aboudorwa metabolomicsinhighgradegliomas |